LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Moody, William E.; Tomlinson, Laurie A.; Ferro, Charles J.; Steeds, Richard P.; Mark, Patrick B.; Zehnder, Daniel; Tomson, C. R. V.; Cockcroft, John R.; Wilkinson, Ian (Ian Boden); Townend, Jonathan N. (2014)
Publisher: Mosby, Inc.
Journal: American Heart Journal
Languages: English
Types: Article
Subjects: Cardiology and Cardiovascular Medicine, Trial Design, R1
Background: There is strong evidence of an association between chronic kidney disease (CKD) and cardiovascular disease. To date, however, proof that a reduction in glomerular filtration rate (GFR) is a causative factor in cardiovascular disease is lacking. Kidney donors comprise a highly screened population without risk factors such as diabetes and inflammation, which invariably confound the association between CKD and cardiovascular disease. There is strong evidence that increased arterial stiffness and left ventricular hypertrophy and fibrosis, rather than atherosclerotic disease, mediate the adverse cardiovascular effects of CKD. The expanding practice of live kidney donation provides a unique opportunity to study the cardiovascular effects of an isolated reduction in GFR in a prospective fashion. At the same time, the proposed study will address ongoing safety concerns that persist because most longitudinal outcome studies have been undertaken at single centers and compared donor cohorts with an inappropriately selected control group.

\ud \ud Hypotheses: The reduction in GFR accompanying uninephrectomy causes (1) a pressure-independent increase in aortic stiffness (aortic pulse wave velocity) and (2) an increase in peripheral and central blood pressure.

\ud \ud Methods: This is a prospective, multicenter, longitudinal, parallel group study of 440 living kidney donors and 440 healthy controls. All controls will be eligible for living kidney donation using current UK transplant criteria. Investigations will be performed at baseline and repeated at 12 months in the first instance. These include measurement of arterial stiffness using applanation tonometry to determine pulse wave velocity and pulse wave analysis, office blood pressure, 24-hour ambulatory blood pressure monitoring, and a series of biomarkers for cardiovascular and bone mineral disease.

\ud \ud Conclusions: These data will prove valuable by characterizing the direction of causality between cardiovascular and renal disease. This should help inform whether targeting reduced GFR alongside more traditional cardiovascular risk factors is warranted. In addition, this study will contribute important safety data on living kidney donors by providing a longitudinal assessment of well-validated surrogate markers of cardiovascular disease, namely, blood pressure and arterial stiffness. If any adverse effects are detected, these may be potentially reversed with the early introduction of targeted therapy. This should ensure that kidney donors do not come to long-term harm and thereby preserve the ongoing expansion of the living donor transplant program.

  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296-305.
    • 2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-S266.
    • 3. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004;66(4):1310-4.
    • 4. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010; 303(10):959-66.
    • 5. Garg AX, Meirambayeva A, Huang A, et al. Cardiovascular disease in kidney donors: matched cohort study. BMJ 2012;344e1203.
    • 6. Krohn AG, Ogden DA, Holmes JH. Renal function in 29 healthy adults before and after nephrectomy. JAMA 1966;196(4):322-4.
    • 7. Moody WE, Chue CD, Inston NG, et al. Understanding the effects of chronic kidney disease on cardiovascular risk: are there lessons to be learnt from healthy kidney donors? J Hum Hypertens 2011;26(3):141-8.
    • 8. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116(1):85-97.
    • 9. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med 2009;360(5):459-69.
    • 10. Fehrman-Ekholm I, Elinder CG, Stenbeck M, et al. Kidney donors live longer. Transplantation 1997;64(7):976-8.
    • 11. Kasiske BL, Anderson-Haag T, Ibrahim HN, et al. A prospective controlled study of kidney donors: baseline and 6-month follow-up. Am J Kidney Dis 2013;62(3):577-86.
    • 12. Moody WE, Edwards NC, Chue CD, et al. Arterial disease in chronic kidney disease. Heart 2013;99(6):365-72.
    • 13. Chue CD, Townend JN, Steeds RP, et al. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010;96(11):817-23.
    • 14. Briet M, Bozec E, Laurent S, et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006;69(2):350-7.
    • 15. Wang MC, Tsai WC, Chen JY, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005;45(3):494-501.
    • 16. Townsend RR, Wimmer NJ, Chirinos JA, et al. Aortic PWV in Chronic Kidney Disease: A CRIC Ancillary Study. Am J Hypertens 2009; 23(3):282-9.
    • 17. Benetos A, Adamopoulos C, Bureau JM, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002;105(10):1202-7.
    • 18. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99(18):2434-9.
    • 19. Blacher J, Pannier B, Guerin AP, et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998;32(3):570-4.
    • 20. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103(7):987-92.
    • 21. Bahous SA, Stephan A, Blacher J, et al. Aortic stiffness, living donors, and renal transplantation. Hypertension 2006;47(2):216-21.
    • 22. DeLoach SS, Meyers KE, Townsend RR. Living donor kidney donation: another form of white coat effect. Am J Nephrol 2012;35(1):75-9.
    • 23. Boudville N, Prasad GV, Knoll G, et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med 2006;145(3): 185-96.
    • 24. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13.
    • 25. Mark PB, Johnston N, Groenning BA, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006;69(10):1839-45.
    • 26. USRDS. U S Renal Data System, Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012. 2012.
    • 27. Chue CD, Edwards NC, Moody WE, et al. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 2012;98(3): 219-24.
    • 28. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121(11):4393-408.
    • 29. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009(113):S1-130.
    • 30. Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol 2009;4(6):1136-9.
    • 31. British Transplantation Society/The Renal Association. United Kingdom Guidelines for Living Donor Kidney Transplantation. 2005.
    • 32. Wei W, Tolle M, Zidek W, et al. Validation of the mobil-O-Graph: 24 h-blood pressure measurement device. Blood Press Monit 2010; 15(4):225-8.
    • 33. Weiss W, Gohlisch C, Harsch-Gladisch C, et al. Oscillometric estimation of central blood pressure: validation of the Mobil-O-Graph in comparison with the SphygmoCor device. Blood Press Monit 2012; 17(3):128-31.
    • 34. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27(21):2588-605.
    • 35. Wilkinson IB, Fuchs SA, Jansen IM, et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998;16(12 Pt 2):2079-84.
    • 36. Frimodt-Moller M, Nielsen AH, Kamper AL, et al. Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease. Nephrol Dial Transplant 2008;23(2):594-600.
    • 37. Savage MT, Ferro CJ, Pinder SJ, et al. Reproducibility of derived central arterial waveforms in patients with chronic renal failure. Clin Sci (Lond) 2002;103(1):59-65.
    • 38. Hametner B, Wassertheurer S, Kropf J, et al. Oscillometric estimation of aortic pulse wave velocity: comparison with intra-aortic catheter measurements. Blood Press Monit 2013;18(3):173-6.
    • 39. Luzardo L, Lujambio I, Sottolano M, et al. 24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation: a feasibility study. Hypertens Res 2012;35(10):980-7.
    • 40. Martensson J, Groth S, Rehling M, et al. Chromium-51-EDTA clearance in adults with a single-plasma sample. J Nucl Med 1998; 39(12):2131-7.
    • 41. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12.
    • 42. Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010;5(6):1003-9.
    • 43. Vickery S, Webb MC, Price CP, et al. Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population. Nephrol Dial Transplant 2008;23(11):3546-53.
    • 44. Landray MJ, Emberson JR, Blackwell L, et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 2010; 56(6):1082-94.
    • 45. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009;53(5):796-803.
    • 46. Maceira AM, Prasad SK, Khan M, et al. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006;8(3):417-26.
    • 47. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 2002; 39(3):750-5.
    • 48. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with twodimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90(1):29-34.
    • 49. Groenink M, de Roos A, Mulder BJ, et al. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998;82(2):203-8.
    • 50. Forbat SM, Mohiaddin RH, Yang GZ, et al. Measurement of regional aortic compliance by MR imaging: a study of reproducibility. J Magn Reson Imaging 1995;5(6):635-9.
    • 51. Yeon SB, Reichek N, Tallant BA, et al. Validation of in vivo myocardial strain measurement by magnetic resonance tagging with sonomicrometry. J Am Coll Cardiol 2001;38(2):555-61.
    • 52. Young AA, Imai H, Chang CN, et al. Two-dimensional left ventricular deformation during systole using magnetic resonance imaging with spatial modulation of magnetization. Circulation 1994;89(2): 740-52.
    • 53. Wiesmann F, Petersen SE, Leeson PM, et al. Global impairment of brachial, carotid, and aortic vascular function in young smokers: direct quantification by high-resolution magnetic resonance imaging. J Am Coll Cardiol 2004;44(10):2056-64.
    • 54. Jackson CE, Shirodaria CC, Lee JM, et al. Reproducibility and accuracy of automated measurement for dynamic arterial lumen area by cardiovascular magnetic resonance. Int J Cardiovasc Imaging 2009;25(8):797-808.
    • 55. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2(5):358-67.
    • 56. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18(12):1440-63.
    • 57. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22(2):107-33.
    • 58. Alam M, Wardell J, Andersson E, et al. Characteristics of mitral and tricuspid annular velocities determined by pulsed wave Doppler tissue imaging in healthy subjects. J Am Soc Echocardiogr 1999;12(8): 618-28.
    • 59. Arena R, Myers J, Abella J, et al. Determining the preferred percentpredicted equation for peak oxygen consumption in patients with heart failure. Circ Heart Fail 2009;2(2):113-20.
    • 60. Doucende G, Schuster I, Rupp T, et al. Kinetics of left ventricular strains and torsion during incremental exercise in healthy subjects: the key role of torsional mechanics for systolic-diastolic coupling. Circ Cardiovasc Imaging 2010;3(5):586-94.
    • 61. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375(9718):895-905.
    • 62. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375(9731): 2073-81.
    • 63. Mafham M, Emberson J, Landray MJ, et al. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS One 2011;6(10):e25920.
    • 64. O'Brien B, Mastoridis S, Sabharwal A, et al. Expanding the donor pool: living donor nephrectomy in the elderly and the overweight. Transplantation 2012;93(11):1158-65.
    • 65. Tavakol MM, Vincenti FG, Assadi H, et al. Long-term renal function and cardiovascular disease risk in obese kidney donors. Clin J Am Soc Nephrol 2009;4(7):1230-8.
    • 66. Rook M, Bosma RJ, van Son WJ, et al. Nephrectomy elicits impact of age and BMI on renal hemodynamics: lower postdonation reserve capacity in older or overweight kidney donors. Am J Transplant 2008;8(10):2077-85.
    • 149.e2 Moody et al
    • 67. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009; 54(6):505-12.
  • No similar publications.